NanoBio and GSK Commence Phase 3 Studies of Nanoemulsion-based OTC Treatment for Cold Sores

ANN ARBOR, Mich.--(BUSINESS WIRE)-- NanoBio® Corporation today announced the initiation of two Phase 3 multicenter trials evaluating NB-001 as a topical treatment for cold sores, a step forward in their OTC licensing agreement with GlaxoSmithKline Consumer Healthcare (GSK CH).

In December 2009, GSK CH licensed exclusive rights in the United States and Canada to NB-001 for the OTC treatment of cold sores. GSK currently offers the market-leading cold sore treatment Abreva, the only OTC medicine approved by the Food & Drug Administration (FDA) to shorten cold sore healing time.

The two trials of NB-001 will be conducted in 1700 subjects at 72 clinical sites and will evaluate the effectiveness of NB-001 to reduce cold sore healing time.

“Based on the efficacy of NB-001 in Phase 2, we are very optimistic about these trials and the path to FDA approval,” said Mary Flack, MD, Vice President of Clinical Research, NanoBio. “Cold sores are painful and embarrassing for the roughly 20 percent of the US population that suffer from them. The initiation of these trials marks a significant step towards the commercialization of a new treatment offering for cold sores, as well as potential other new offerings to come from our nanoemulsion-based platform technology.”

The trials are currently enrolling and are expected to conclude in 2012.

About NanoBio

NanoBio Corporation is a privately-held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat® technology platform. The company’s lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.



CONTACT:

NanoBio Business Development
John Coffey, 734-302-9107
[email protected]
or
Schwartz Communications
Media:
Stacey Holifield, 781-684-0770
Brianne Donahue, 781-684-0770
[email protected]

KEYWORDS:   United States  North America  Michigan

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical  General Health

MEDIA:

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.